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a b s t r a c t
Despite enormous progress in medicine, symptomatic cerebral vasospasm (CVS), remains
an unexplained clinical problem, which leaves both physicians and patients helpless and
relying on chance, due to the lack of speciﬁcmarker indicative of imminent danger aswell as
the lack of speciﬁc treatment. In our opinion CVS occurrence depends on dynamic dis-
balance between free radicals' formation (oxidative stress) and antioxidant activity.
Isoprostanes are products of free-radical peroxidation of polyunsaturated fatty acids, and
seem to mark a promising path for the research aiming to unravel its possible mechanism.
Not only are they the biomarkers of oxidative stress in vivo and in vitro, but also have
manifold biological effects (including vasoactive, inﬂammatory and mitogenic) via activa-
tion of the thromboxaneA2 receptor (TBXA2R), both in physiological and pathophysiological
processes. This review addresses the importance of isoprostanes in CVS in quest of
appropriate biomarkers.
© 2018 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.1. Introduction
Based on the recent literature, there is growing evidence
supporting the clinical association between lifestyle/environ-
mental risk factors, oxidative stress (OS) and endothelial
dysfunction [1,2]. An unbalanced production of toxic oxygen* Corresponding author.
E-mail address: karol.lek@poczta.fm (K. Wiśniewski).
https://doi.org/10.1016/j.pjnns.2018.09.009
0028-3843/© 2018 Published by Elsevier Sp. z o.o. on behalf of Polish Nspecies, reactive oxygen species (ROS) and endogenous anti-
oxidants,may be the cause of a disease [3]. ROS can activate the
transcription factor NF-kappaB, which hasmany inﬂammatory
cytokines genes among its target genes [4]. The identiﬁcation of
cytokines asmediators of inﬂammation led to ‘‘cytokine theory
of disease’’ [5]. Additionally, inﬂammation as consequence of
chemical, physical or psychological changes, can induce OS [6].eurological Society.
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molecules effector, which have short half-lives, ranging from
nanoseconds to milliseconds [7]. This makes it impossible to
measure ROS in biological samples and wemust rely on signs,
chemicals that are produced by the interaction of ROS with
various cellular molecules [8]. They take part in the peroxida-
tion ofmembrane lipids of endothelial cells. Thus, recently F2-
isoprostanes (F2-IsoPs, IsoPs) have been demonstrated to be
the most speciﬁc markers of lipid peroxidation in vivo. They
are considered oxidative stress markers, as their concentra-
tion directly reﬂects the free radical content. F2-IsoPs are
compounds similar to prostaglandins, generated via nonen-
zymatic, free radical peroxidation of polyunsaturated fatty
acids, in particular, arachidonic acid [9].
An inﬂammatory response often results in tissue damage
(e.g. rheumatoid arthritis) and loss of function. Endothelial
dysfunction is clearly associated with oxidative stress, and is
also the ﬁrst clinical correlate of atherosclerosis that can be
diagnosed [10,11].
Our aim was to review the current state of knowledge but
also to provide new concepts to understand the vital crosstalk
of the different systems (stress response pathways and redox
signalling machinery) involved in the CVS pathophysiological
processes and to reveal probable disease pathways that may
explain vasoconstrictive effect observed in CVS.
In this revision, we focused on the role of F2-IsoPs as
a biomarker of oxidative stress in CVS after aneurysmal
subarachnoid haemorrhage (aSAH).
1.1. Evidence acquisition
We conducted a review of the pertinent literature paying
careful attention to large animal laboratory research and
clinical studies. Unfortunately, there are no randomized
controlled prospective clinical studies on F2-IsoPs. After a
brief summary on oxidative stress and biological properties of
IsoPs, we discussed the role of F2-IsoPs in CVS.2. Clinical implications
2.1. Oxidative stress
OS is a disorder of homeostasis leading to an increase in the
concentration of ROS. This tips the peroxidation – antioxidant
balance towards the oxidation reaction and leads to disruption
of redox signalling (RS) and physiological function [3].
The main endogenous sources of primary type of ROS,
superoxide anion radical (O2
), are mitochondria. They
contain electron-transportation chain (ETC) which major
function is ATP production through the process of oxidative
phosphorylation, while ROS are by-products of ETC function-
ing. ETC transfers high-energy electrons from NADH or FADH2
to the ﬁnal electrons acceptor – O2. Another source of O2
 are
NADPH-oxidases of Nox family enzymes that produce ROS as a
primary product. PhagocyticNADPH-oxidase (NOX2) is theﬁrst
identiﬁed ROS-generating enzyme. It has been documented
that O2
 production in neutrophils and macrophages parti-
cipates in antibacterial signal transduction [12]. ROS produc-
tion is controlled by endogenous antioxidants like glutathioneand reactions catalyzed by peroxyredoxins and glutathione
peroxidase.
RS works through discrete, reversible modiﬁcations/
changes like cysteine residues include S-nitrosylation/S-
nitrosation, sulfenylation, disulﬁde bonds and S-glutathiony-
lation [13,14]. Under physiological condition RS, through ROS
and reactive nitrogene species (RNS), induces changes in
activities of proteins which are elements of complex networks
of kinases, phosphatases, ion channels, apoptotic cascades
and can cause changes in transcriptional activity [13,15,16].
RS regulates cell-signalling, vascular tension, homeostatic
control, immunological response and pregnancy [17,18]. Even
slight variations of lipid oxidation in vivo are vital to correct
functioning of an organism. On the other hand, a rapid
accumulation of biologically active oxidation by-products
which overcomes the cellular reductive capability, results in
DNA, protein and lipid damage, thus disrupting the cell
environment and ﬁnally leading to cell's death. Most impor-
tantly, damaged cells also produce reactive oxygen species
creating a self-perpetuating vicious cycle which, if not
interrupted, culminates in injury and disease.
The main problem arises from the evaluation of highly
reactive and unstable free radicals. However, the recent
discovery of isoprostanes has opened up new possibilities
for the research.
2.2. Isoprostanes as oxidative stress markers
OS is induced for research purposes with carbon tetrachloride
using animalmodels [19]. Suchmodelswere also employed for
establishing F2-isoprostanes as oxidative stress markers [20].
Isoprostanes are compounds similar to prostaglandins,
generated during non-enzymatic, free-radical peroxidation of
multi-unsaturated fatty acids, mainly arachidonic acid [9].
They are considered oxidative stress markers, since their
concentration directly correlates with the concentration of
free oxygen species. The analysis of isoprostanes broadened
the understanding of the role of free radicals in human
physiology and pathophysiology, especially with reference to
vascular diseases. Isoprostanes are found in urine, blood,
cerebrospinal ﬂuid, and also exhaled air. Their main metabo-
lite, 2,3-dinor-5,6-dihydro-8-iso-PGF2a, is mostly expelled by
kidneys. Importantly, there are same data which suggest that
F2-IsoPs are conjugated with glucuronide and excreted to the
urine. One should keep in mind another route of F2-IsoP
metabolism when measuring these compounds in urine [21].
The half-life of isoprostanes is approximately 16 min. Plasma
concentration of free 8-iso-PGF2a varies from 10 to 80 pg/ml
(average 28 pg/ml), depending on the time of day [22].
The level of isoprostanes increases in various diseases:
neurodegenerative (AD, HD, CJD, and MS), cirrhosis, athero-
sclerosis (hypercholesterolemia, hyperhomocysteinemia), di-
abetes mellitus, heart diseases, severe cholestasis, allergic
asthma, adult respiratory distress syndrome, kidney distress
syndrome, retinopathy and chronic obstructive pulmonary
disease [23].
Appropriate collection and storage procedures are the key
to repeatable results. Artefactual oxidation of lipids during
storage could occur due to haemolysis of blood samples. To
minimize this effect blood should be collected to tubes
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the centrifugation should be performed as soon as possible
(by that time it should be kept chilled). Plasma should be
aliquoted and stored at 80 8C not 20 8C, because autoxida-
tion can occur at 20 8C leading to artefactual generation of
F2-IsoPs ex vivo. Tissue samples should be ﬂash frozen
immediately after collection and also stored at 80 8C. The
antioxidants butylated hydroxytoluene to minimize artefac-
tual elevation of F2-IsoPs should be used, especially when
samples cannot be immediately centrifuged and snap frozen
in liquid nitrogen [24].
Currently, three techniques are used to measure F2-IsoPs:
gas chromatography–mass spectrometry (GC/MS), liquid chro-
matography–mass spectrometry (LC/MS) and immunoassays
(ELISAs). Mass spectrometric-based assays are widely accepted
as the most accurate methodologies, especially GC/MS,
because of its greater sensitivity [25]. The use of ELISA to
quantify urine F2-IsoPs, despite its simplicity and cost-
effectiveness, may be associated with cross-reactivity with
other isoprostane isomers [26].
F2-IsoPs in plasmamostly are quantiﬁed as free fatty acids.
Since these compounds are found esteriﬁed in phospholipids
in the plasma, base hydrolysis should be performed to analyze
total F2-IsoPs in the plasma. F2-IsoPs can be directly excreted
into the urine without metabolism, so that if renal disease
coexists with oxidative damage, their urine levels are falsiﬁed
and actual changes in total body lipid peroxidation should be
checked.
Establishing speciﬁc thresholds of the level of isoprostanes
may be helpful in early detection and prevention of distinct
disorders. Moreover, such analysis may offer a non-invasive
way of monitoring the course of disease.
With regard to CVS, a biological marker of the developing
pathology may help in recognizing the impending exacerba-
tion and enable an early management.
2.3. Biological properties of isoprostanes
The formation of prostaglandin-like compounds (IsoPs) as
products of free-radical peroxidation of arachidonic acid was
ﬁrst described by Pryor and Godber in 1991. These structures
were deﬁned as F2-IsoP due to their prostanoid 1,3-dihydrox-
ycyclopenthane ring (ring F), analogous to prostaglandins F
(PGF2 a). F2-IsoP are the structural isomers of prostaglandins,
which consists of a cyclopentane ring and two side chainswith
double bonds and ahydroxyl group. The distinguishing feature
is the conformation of the side chains in relation to ring F: F2-
isoprostane is a cis-, while PGF2a a trans-conformer [27].
The isoprostanes forming mechanism is associated with
the presence of ROS (such as HO, RO, ROO, O2) which detach
the hydrogen atom from polyunsaturated fatty acids and
propagate a chain reaction. This reaction occurs at positions C-
13, C-10 and C-7 of arachidonic acid and may result in three
radical forms, exposed to further internal cyclization. Through
reduction, each of them gives rise to four regioisomers with
ring F, which, in turn, may form eight racemic diastereomers
each. Thus, 96 different compounds are generated in different
amounts [28]. The formation of isoprostanemay occur via two
peroxidation routes [29,30] – by endoperoxide and dioxetane
mechanisms.Bioactive isoprostanes (mainly 8-iso-PGF2a and 8-iso-
PGE2a) are formed in various tissues, while their unmetabo-
lized portion can be found in plasma. Local hormones reach
their biological properties in tissues with low or high
concentrations in plasma and reduce them after esteriﬁcation.
Tissue hydrolases revert the esteriﬁed IsoPs into potent
mediators which affect the cellular membrane integrity and
ﬂuidity, exacerbating the oxidative stress reaction. These
compounds are mainly formed in tissues in esteriﬁed forms,
which act as substrates for the hydrolytic activation by speciﬁc
enzymes [31,32]. Then in the free-acid form isoprostanes are
released into blood. Nonetheless, their physiological function
and pharmacokinetics are not well-understood.
The most extensively analyzed isoprostane, 8-iso-PGF2a,
causes vasoconstriction in renal and pulmonary circulatory
systems, as well as induces DNA synthesis in smooth muscle
cells [34]. The 8-iso-PGF2a stimulate endothelial cell and
smooth muscle cell proliferation. [35]. Still, their mechanisms
of action are vaguely deﬁned. Mitogenesis and stimulation of
platelet aggregation are achieved via the thromboxane
receptor [33,34], however, several reports indicate the exis-
tence of a speciﬁc receptor for isoprostanes [35,36]. In addition,
other F2-izoP, 12epi-PGF2, stimulate ﬁbroblast proliferation
through PGF2a receptors [37]. Vasoconstriction is a well-
known effect of isoprostanes, particularly 8-iso-PGF2a ob-
served in various organs, including brain, kidney, lung,
pulmonary arteries and retinal vessels [38,39]. It depends on
the concentration of extracellular calcium ions and, possibly,
of protein kinase C [34,40]. In addition, 8-iso-PGF2a induces the
formation of a cyclooxygenase-dependent prostacyclin PGF2a
[41] as well as thromboxane in the endothelium [39].3. Future directions
3.1. Isoprostanes in cerebral vasospasm after aneurysmal
subarachnoid haemorrhage
The most common and fatal, yet the least understood
complication of aSAH is CVS, as it leads to delayed ischaemic
neurologic deﬁcit resulting from irreversible vasoconstriction
caused by proliferative angiopathy [42,43]. CVS is always taken
into consideration in aSAH patients presenting with symp-
toms of confusion or decreased level of consciousness with or
without focal neurologic deﬁcits (speech or motor).
From the histopathological point of view, in the course of
CVS, between day 1 and day 9, one observes increased
percentage of inﬂammatory cells (lymphocytes, plasmocytes,
and mast cells) in the adventitia, necrosis and the loss of
elasticity in smooth muscles, as well as thickening, swelling,
vacuolization and loosening of intracellular connections in the
endothelium. Furthermore, between day 9 and day 60,
proliferation of smooth muscles and irreversible thickening
of the intermediate layer of the vessel are also observed [44,45].
Up to now, numerous theories aiming to explain the
occurrence of CVS have been proposed, but its speciﬁc
mechanism has not been deﬁned, yet. The most plausible
theory suggests that the extravasated blood acts as the nidus
for inﬂammatory factors, which lead to CVS. Extravasated
haemoglobin leads to ROS release and OS. This results in RS
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endothelial cells and perivascular adipose tissue, as well as
proliferation of smooth muscle cells. The extravasated
haemoglobin is bound to haptoglobin (HP), which may be
found in two forms. HP 1-1 binds with a lower afﬁnity [46,47],
while HP 2-2 induces a cascade of inﬂammatory reactions,
elevating the concentration of cytokines, leukocytes and cell
adhesion molecules [46,48].
As aforementioned, RS which is modiﬁed by ROS, regulate
the vascular tone in various mechanisms, called ‘‘redox
switches’’ leading to endothelial dysfunction and vasocon-
striction.
The ﬁrst of ‘‘redox switches’’ involves endothelial NO
synthase (eNOS). The mechanisms underlying eNOS uncou-
pling include S-glutathionylation of the eNOS reductase
domain, eNOS phosphorylation (H2O2/ONOO
mediate activa-
tion of protein kinase C (PKC) and protein tyrosine kinase-2
(PYK-2) dependent eNOS phosphorylation). Furthermore,
direct oxidation depletes eNOS cofactor – tetrahydrobiopterin,
regulates dimethylarginine (ADMA) synthesis/break-down
and disrupts the zinc–sulphur complex in the dimer binding
interface. It is also known that cerebrospinal ﬂuid (CSF) ADMA
levels are closely associatedwith the degree and time course of
vasospasm (when CSF ADMA levels decrease, vasospasm
resolves) [49,50]
The other switches have to dowith soluble guanylyl cyclase
(sGC) which is a key enzyme of the nitric oxide (NO) signalling
pathway. Upon binding of NO to a prosthetic heme group on
sGC, the enzyme catalyses synthesis of the secondmessenger
– cyclic guanosine monophosphate (cGMP), which produces
vasorelaxation and inhibits smooth muscle proliferation,
leucocyte recruitment and platelet aggregation through a
number of downstreammechanisms. OS leads to an impaired
NO

/cGMP-signalling by oxidative inhibition of sGC via oxida-
tion of Cys122, making the enzyme less sensitive to NO

.
Additionally, oxidation promote depletion of the hememoiety
[51–53].
The third switch comprises the endothelin-1 (ET-1) and
NADPH oxidase system since oxidants can lead to increased
expression of ET-1 and potentiate its vasoconstrictory proper-
ties, which can be further self-ampliﬁed by ET-1 dependent
activation of NADPH oxidase [54–56].
The last switch relates to prostanoid synthesis (PGIS).
The key enzyme of PGIS, cyclooxygenase, is activated at
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Fig. 1 – ADMA, dimethylarginine; BH4, tetrahydrobiopterin; PKC
endothelial NO synthase; sGC, soluble guanylyl cyclase; ET-1, enlow peroxide levels, thus oxidative stress promotes isopros-
tanes formation [57,58]. Reduced synthesis of prostacyclin
in the vessel wall might also contribute to the cerebral
vasospasm [59].
Activation of all of these redox switches by ROS (most likely
hydrogen peroxide and superoxide) alters endothelial and
vascular function, which will favour vasoconstriction. These
switches are usually activated simultaneously and one ﬁnds
eNOS uncoupling, sGC desensitization and PGIS synthesis/
break-down along with isoprostane formation or up-regulated
ET-1 signalling at the same time. It is worth mentioning that
8-Iso-PGF2 has been shown to stimulate ET-1release in a dose-
dependent manner [60]. ET-1 has been well investigated as
important mediator of CVS [61] (Fig. 1).
In our opinion isoprostanes play a vital role in CVS,
disturbing endothelial integrity and leading to vasoconstric-
tion. These compounds inform as abut the level of OS and
indirectly about ‘‘redox switches’’ condition. They are crucial
biomarkers of CVS. We have reported elevated urine F2-IsoPs
levels in patients following aSAH compared with healthy
controls, which may reﬂect the increased oxidative stress in
patients after aSAH. We observed that increased F2-IsoPs on
day 3 after surgery were associated with greater risk of CVS
and worse long-term outcomes. Moreover, the ROC curves
plotted for prediction of CVS and GOS score 4 at 4months after
surgery with day 3 F2-IsoPs had AUC >0.8, what indicates the
potential clinical value of these markers. We also employed
logistic regression models combining F2-IsoPs with clinical
features to investigate whether such an approach might
further improve the prediction rate. This analysis produced
perfectly ﬁtted models, which resulted from the small group
size and the associated overﬁtting. To limit its impact, we
performed the same analysis after resampling and stratiﬁed
cross-validation, obtaining more adequate ROC curves. Thus,
although both issues are associated, based on the periopera-
tive clinical condition and F2-IsoP levels the risk of CVSmay be
more effectively predicted than the long-term outcome. The
latter is undoubtedly affected by anumber of other factors. The
association of the F2-IsoPs levels with risk of CVS may offer a
new insight into the pathogenesis of this poorly understood
condition [62]. Additionally, F2-IsoPs as biologically active
chemicals, start cascade reactions leading to irreversible
vasoconstriction. These results, together with the various
biological activities of 8-iso-PGF2a, suggested that 8-iso-PGF2a,, protein kinase C; PYK-2, protein tyrosine kinase-2; eNOS,
dothelin-1; NOX, NADPH oxidase; COX, cyclooxygenase.
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ase and lipoxygenase, could be assumed to be at least one of
the causes of delayed cerebral vasospasm. We can differenti-
ate two mechanism connected to IsoPs which are observed in
CVS. The ﬁrst, is a calcium-dependent process and the second
are calcium-independent molecular events, both lead to
smooth muscle contraction.
F2-IsoPs have probably slightly different calcium-depen-
dent processes. 8-iso-PGF2 trigger an increase in intracellular
Ca2+ that is dependent on extracellular Ca2+. Since nifedipine
did not inhibit the effects of 8-iso-PGF2, possibly the L-type
voltage-gated Ca2+ channels are not implicated in vasocon-
striction. Other studies performed with Ca2+ entry blocker,
including that by non-voltage-dependent Ca2+ channels
showed that non-voltage-gated Ca2+ channels are involved
in the vasoconstrictor action of 8-iso-PGF2 [63–65].
Calcium-independent smooth muscle contraction follow-
ing SAH begins with PKC activation by the phospholipase C
mediated release of diacylglycerol (DAG) and inositol-triphos-
phate (IP3) initiated by ligand binding to G-protein coupled
membrane receptors [66]. PKC is activated as shown in the ﬁrst
‘‘redox switch’’, but it is worth mentioning that, 8-iso-PGF2
stimulates IP3 synthesis [67,68]. Activated PKC phosphorylates
caldesmon and caldesmin resulting in a prolonged constric-
tion. Furthermore, PKC alters several other intracellular
signalling pathways including mitogen activated protein
kinase, protein tyrosine kinase (PYK-2) and Rho kinase [66].
RhoA (Ras homolog gene family protein, member A) translo-
cation activates its downstream target Rho kinase inhibiting
myosin light chain kinase (MLC) phosphatase activity to
increase the amount of phosphorylated MLC, leading to a
prolonged contraction without Ca2+ elevation [69,70]. RhoA
and Rho kinasemessenger RNAs are up-regulated in sustained
vasospasm, a RhoA/Rho kinase activation is found in canine
basilar arteries, and vasospasm is partially reversed by the Rho
antagonist [66,71].
[(Fig._2)TD$FIG]
Fig. 2 – OS, oxidative stress; IP3, inositol-triphosphate; DAG, diacy
potential proteins, non-voltage-gated Ca2+ channels; PKC, protein
activated protein kinase; MLC, myosin light chain kinase.It has also been shown that 8-iso-PGF2 constricts cerebral
vessels, which can be inhibited by thromboxane receptor
antagonists [72,73]. It raises suspicion that IsoPs bioactivity
is achieved via the thromboxane receptor [74,75]. The
biological actions of the thromboxane (TP) receptor are
achieved through activation of one or both of its isoforms
(TPa and TPb) that are produced through differential splicing
of a single gene product [76,77]. Both isoforms are members of
the G-protein-coupled receptor superfamily that differ with
regard to their C termini [78]. G-protein coupled receptors are
associated with an intracellular calcium release via IP3 and
DAG [79–81]. Stimulation of G-protein-coupled receptor results
in activation of phospholipase C (PLC). This leads to hydrolysis
of phosphatidylinositol 4,5-bisphosphate and generation of
DAG and IP3, resulting in activation of PKC and Ca2+ release
from intracellular stores. DAG stimulates PKC which activates
phospholipase A2, an enzyme responsible for the release of
arachidonic acid from membrane phospholipids [82] (Fig. 2).
Obviously enough, different polymorphic variants of
thromboxane receptor (especially in positions rs2238633,
rs2238632 and rs768963), are related to the concentration of
the transcript and, hence, determine the receptor concentra-
tion on the cell surface, which is associated with varying
intensity of the response to the ligand [83,84].
However, several reports indicate that probably there exists
a speciﬁc receptor for isoprostanes, so 8-iso-PGF does not
directly bind with the thromboxane receptor [85,86]. Altogeth-
er, these data suggest that 8-iso-PGF2 increases inﬂux of Ca2+
possibly via receptor-operated channels [87,88], which in turn
leads to stimulation of endothelin release and, more impor-
tantly, activation of phospholipase A2 and metabolism of
arachidonic acid into prostanoids, amongwhich thromboxane
predominates inmediating 8-iso-PGF2 – induced vasoconstric-
tion. The involvement of a receptor-operated Ca2+ channel
would be consistent with the existence of a distinct 8-iso-PGF2
receptor site, which remains to be characterized [67].lglycerol; PLA2, phospholipase A2; TRPCs, transient receptor
kinase C; PYK-2, protein tyrosine kinase-2; MAPK, mitogen
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and rapidly expanding superfamily of non-voltage-gated Ca2+
channels. TPRs are coded by the TRPC 3,4,5,6,7 genes and are
promising proteins for the 8-iso-PGF2 receptor. Accumulated
evidence strongly suggests that especially TRPC6may serve as
a major Ca2+ entry channel that integrates various mecha-
nisms regulating the arterial tone [89], via DAG [81,90]. The
scientiﬁc literature widely describes, that endothelin-1 acti-
vate TRPC6-like cationic currents to cause Ca2+ increase [91]
(Fig. 2).
It is also now recognized that perivascular adipose tissue
contributes to vascular homeostasis by producing vasoactive
compounds such as adipokines, ROS, NO

and promote
endothelial dysfunction from outside the vessel, which
answered the question, by whichmechanism the perivascular
blood causes endothelial dysfunction leading to CVS [92,93].
Literature data suggest, that the types of IsoPs that will be
formed and in what ratio, depend on oxygen tension and
glutathione concentration [94]. The role of antioxidants in
patients with CVS remains unexplained. Some evidence
suggests that their level is decreased after aSAH. Mean levels
of retinol, b+g-tocopherol, d-tocopherol, b-carotene, lutein,
and coenzyme Q10, but not a-tocopherol, in plasma were
signiﬁcantly lower in SAHpatients than in controls [95]. On the
other hand, it has been shown that oral coenzyme Q10
administration and intracisternal administration of a-tocoph-
erol could suppress vasospasmand ischaemic brain damage in
experimental SAH [96,97]. NRF2 is the main transcriptional
regulator of cellular homeostasis and the protector against
multiple stress conditions. Upon dimerization with small MAF
proteins, it recognizes an enhancer in the promoter region of
target genes, knowns as Antioxidant Response Element/
Electrophile Responsive Element genes. These accounts for
about 1% of human genome and encode phase I, II and III
detoxiﬁcation enzymes; glutathione, peroxiredoxin [98].
In our opinion CVS depends on dynamic disbalance
between free radicals' formation (oxidative stress) and
antioxidant activity. IsoPs start cascade reactions leading to
arterial wall changes which in turn cause irreversible
vasoconstriction as was shown in histopathological studies.
4. ConclusionsThe speciﬁc mechanism of CVS has not been deﬁned yet. The
most plausible theory suggests that:1. The extravasated haemoglobin leads to ROS release and
OS.2. This results in redox signalling changes, which implicate
peroxidation of perivascular adipose tissue and endothelial
cell membrane lipids, followed by the proliferation of
smooth muscle cells.3. Perivascular adipose tissue promotes endothelial dysfunc-
tion from the outside the vessel, which explains the link
between perivascular blood and endothelial dysfunction.4. Moreover, ROS-dependent redox signalling regulates the
vascular tone in various mechanisms, called ‘‘redox
switches’’, leading to further endothelial dysfunction and
vasoconstriction.5. These switches are usually activated simultaneously and
function in parallel. The key enzyme of PGIS synthesis,
cyclooxygenase, is activated at lowperoxide levels,while, in
turn, oxidative stress promotes IsoPs formation.6. IsoPs are considered as oxidative stressmarkers, since their
concentration directly correlates with the concentration of
free oxygen species.7. Still, their mechanisms of action are vaguely deﬁned.
Stimulation of endothelial cell, smooth muscle cell and
stimulation of platelet aggregation are achieved via the
thromboxane receptor, however, several reports indicate
the probable existence of a speciﬁc receptor for isopros-
tanes.8. The vasoconstrictor action of IsoPs is not inhibited by a
calcium channel blocker (nifedipine) because they work
through a G-protein-coupled receptor (thromboxane recep-
tor), which are associated with an intracellular calcium
release via IP3 and DAG.9. The types of IsoPs that will be formed and in what ratio,
depend on oxygen tension and antioxidant mechanisms.
To sum up, it may be concluded that CVS is a dynamic
disbalance between free radicals' formation and antioxidant
activity.
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